K. Gold

E. Dmitrovsky, J. Heymach, A. Vaporciyan, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA4EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK+ NON–SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES

A. Shaw, S. Gettinger, R. Salgia, 2015 .

Scirrhous carcinoma: A previously undescribed tumor of the oral cavity

K. Gold, R. Orosco, A. Finegersh, 2021, Clinical case reports.

Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.

D. Gomez, Z. Liao, L. Levy, 2013, International journal of radiation oncology, biology, physics.

Rapid onset type 1 diabetes with anti-PD-1 directed therapy

G. Daniels, K. Gold, S. Patel, 2020, Oncotarget.

Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): An analysis of the Surveillance, Epidemiology, and End Results (SEER) registry.

Edward S. Kim, S. Lippman, J. Lee, 2012 .

Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis.

S. Lippman, I. Wistuba, J. Lee, 2017 .

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

M. Socinski, A. Shaw, S. Ou, 2016, The Lancet. Oncology.

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.

J. Becker, J. Bourhis, F. Ciardiello, 2021, Cancer treatment reviews.

A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

K. Messer, K. Gold, E. Cohen, 2022, Oral oncology.

Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma

D. Fraker, S. Mandel, V. Livolsi, 2007 .

A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).

M. Socinski, A. Shaw, S. Ou, 2015 .

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

M. Socinski, A. Shaw, Gregory Riely, 2015, The Lancet. Oncology.

Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial

J. Lee, K. Gold, W. William, 2018, Cancer.

Treatment of Disseminated Non-Melanoma Skin Cancers

K. Gold, M. Kies, 2011 .

Development of Care Pathways to Standardize and Optimally Integrate Multidisciplinary Care for Head and Neck Cancer

Charles S. Coffey, J. Califano, G. Daniels, 2018, Oncology Issues.

Natural-agent mechanisms and early-phase clinical development.

S. Lippman, K. Gold, Janet Wang, 2013, Topics in current chemistry.

Role of molecular markers and gene profiling in head and neck cancers

Edward S. Kim, K. Gold, 2009, Current opinion in oncology.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

E. Smit, Melissa L. Johnson, E. Felip, 2022, Journal of Clinical Oncology.

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Melissa L. Johnson, P. Janne, Dong-Wan Kim, 2021, Cancer discovery.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

P. Jänne, Melissa L. Johnson, Dong-Wan Kim, 2021 .

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study

D. Ettinger, M. Kris, M. Socinski, 2017 .

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.

S. Lippman, M. V. Estrada, G. Daniels, 2021, The Lancet. Oncology.

The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL

C. Creighton, D. Gibbons, Dong-Hoon Shin, 2016, Scientific Reports.

Prevention of Bronchial Hyperplasia by EGFR Pathway Inhibitors in an Organotypic Culture Model

Edward S. Kim, J. Koo, W. Hittelman, 2011, Cancer Prevention Research.

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

Michael L. Wang, J. Minna, J. Roth, 2014, Journal of the National Cancer Institute.

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy

L. Bazhenova, K. Gold, S. Patel, 2021, Translational lung cancer research.

Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics

J. Califano, L. Mell, J. S. Gutkind, 2019, Clinical Cancer Research.

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.

P. Thompson, K. Gold, E. Cohen, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalizing lung cancer prevention through a reverse migration strategy.

Edward S. Kim, W. Hong, I. Wistuba, 2013, Topics in current chemistry.

Adjuvant Chemotherapy Following Surgery for Lung Cancer

K. Gold, 2014 .

An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis

G. Daniels, F. Worden, K. Messer, 2020 .

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

C. Rudin, R. Govindan, A. Chaudhuri, 2019, Clinical Cancer Research.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

P. Jänne, L. Sequist, J. Wolf, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2014 .

Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort

S. Lippman, I. Wistuba, J. Lee, 2023, Cancer.

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Michael Thomas, Yi-long Wu, E. Felip, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it.

B. Beadle, K. Gold, M. Bhayani, 2013, JAMA otolaryngology-- head & neck surgery.

Targeted therapies in squamous cell carcinoma of the head and neck

Edward S. Kim, Ho-Yyoung Lee, K. Gold, 2009, Cancer.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

T. Clackson, A. Shaw, S. Gettinger, 2016, The Lancet. Oncology.

ROS1--targeting the one percent in lung cancer.

K. Gold, 2014, The New England journal of medicine.

New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

Edward S. Kim, I. Wistuba, K. Gold, 2012, Clinical Cancer Research.

Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy

Edward S. Kim, Diane D. Liu, W. Hong, 2013, Clinical Cancer Research.

Afatinib in the treatment of head and neck squamous cell carcinoma

K. Gold, R. Ferrarotto, 2014, Expert opinion on investigational drugs.

Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma

A. Garden, J. Lee, E. Sturgis, 2016, Cancer.

FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer.

J. Erasmus, K. Gold, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

New strategies in immunotherapy for non-small cell lung cancer.

K. Gold, D. Carrizosa, 2015, Translational lung cancer research.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy

Edward S. Kim, R. Munden, I. Wistuba, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration

Edward S. Kim, W. Hong, I. Wistuba, 2011, Cancer Prevention Research.

An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.

J. Nieva, G. Daniels, A. Colevas, 2017 .

The impact of the COVID-19 pandemic on stage at diagnosis of breast and colorectal cancers.

K. Gold, R. Shatsky, A. Banerjee, 2021, Journal of Clinical Oncology.

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

P. Iyengar, B. Loo, A. Chiang, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2015 .

Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity‐modulated radiotherapy

A. Garden, C. Fuller, B. Beadle, 2016, Head & neck.

Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Edward S. Kim, K. Coombes, Jing Wang, 2012, Cancer Prevention Research.

A Hospital-Wide Intervention to Improve Compliance With TNM Cancer Staging Documentation.

J. Califano, K. Gold, F. Faraji, 2021, The Journal of the National Comprehensive Cancer Network.

Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry

Yan Xing, Edward S. Kim, Jianjun Zhang, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intra-tumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multi-region Sequencing

Yuanqing Ye, Harshad Mahadeshwar, David C. Wedge, 2015 .

Sleep and Breathing … and Cancer?

S. Lippman, A. Malhotra, P. Peppard, 2016, Cancer Prevention Research.

Planning for post‐pandemic cancer care delivery: Recovery or opportunity for redesign?

B. Karlan, H. Rugo, R. Bold, 2020, CA: a cancer journal for clinicians.

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.

J. Nieva, Melissa L. Johnson, L. Byers, 2021, Journal of Clinical Oncology.

1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA.

T. Clackson, A. Shaw, S. Gettinger, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Xin Zhang, T. Clackson, A. Shaw, 2018, Frontiers in Oncology.